SOPHiA GENETICS CSO sells 4,000 shares in plan

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu completed an open-market sale of 4,000 Ordinary Shares on July 13, 2026, at a weighted average price of $5.7048 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu completed an open-market sale of 4,000 Ordinary Shares on July 13, 2026, at a weighted average price of $5.7048 per share. The transaction was made under a duly adopted Rule 10b5-1(c) trading plan, and Xu now directly holds 610,887 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares

Net Sell 1 txn

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 4,000 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	4,000	$5.7048	$23K

Holdings After Transaction: Ordinary Shares — 610,887 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.54 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 4,000 Ordinary Shares Weighted average sale price: $5.7048 per share Post-transaction holdings: 610,887 Ordinary Shares +1 more

4 metrics

Shares sold 4,000 Ordinary Shares Open-market sale by Chief Scientific Officer on July 13, 2026

Weighted average sale price $5.7048 per share Price for the 4,000 Ordinary Shares sold

Post-transaction holdings 610,887 Ordinary Shares Direct ownership by Zhenyu Xu after the sale

Sale price range $5.54 to $5.79 per share Range of individual trade prices within the 4,000-share sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale of Ordinary Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title: Ordinary Shares of SOPHiA GENETICS SA"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPHiA GENETICS (SOPH) report for Zhenyu Xu?

SOPHiA GENETICS reported that Chief Scientific Officer Zhenyu Xu executed an open-market sale of company shares. On July 13, 2026, he sold 4,000 Ordinary Shares pursuant to a pre-arranged Rule 10b5-1(c) trading plan at a weighted average price of $5.7048 per share.

How many SOPHiA GENETICS (SOPH) shares did Zhenyu Xu sell and at what price?

Zhenyu Xu sold 4,000 Ordinary Shares of SOPHiA GENETICS. The sale occurred at a weighted average price of $5.7048 per share, with multiple trades executed within a price range from $5.54 to $5.79, as disclosed in the transaction details.

How many SOPHiA GENETICS (SOPH) shares does Zhenyu Xu hold after the sale?

Following the reported sale, Zhenyu Xu directly holds 610,887 Ordinary Shares of SOPHiA GENETICS. This share balance reflects his position after disposing of 4,000 shares in the July 13, 2026 open-market transaction executed under a Rule 10b5-1(c) plan.

Was the SOPHiA GENETICS (SOPH) insider sale by Zhenyu Xu under a Rule 10b5-1 plan?

Yes. The disclosure states the transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan. Such plans pre-schedule trades, meaning the 4,000-share sale on July 13, 2026 followed predetermined instructions rather than discretionary timing.

What type of security did SOPHiA GENETICS (SOPH) insider Zhenyu Xu sell?

Zhenyu Xu sold Ordinary Shares of SOPHiA GENETICS. The Form 4 identifies a single non-derivative transaction: an open-market sale of 4,000 Ordinary Shares at a weighted average price of $5.7048 per share, leaving him with 610,887 Ordinary Shares held directly.

What role does Zhenyu Xu hold at SOPHiA GENETICS (SOPH) in relation to this insider trade?

In this reported transaction, Zhenyu Xu is identified as SOPHiA GENETICS’ Chief Scientific Officer. The Form 4 records his capacity as an officer and shows his direct ownership of company Ordinary Shares before and after the 4,000-share open-market sale on July 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/13/2026		S		4,000(1)	D	$5.7048(2)	610,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.54 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)